Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 2:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 63 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Escherichia Coli Infection Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study of ETEC Vaccine

NCT01147445
View directory record Official record
Conditions
Gastroenteritis Escherichia Coli
Interventions
Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
Baltimore, Maryland • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Jun 26, 2026, 2:33 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections

NCT05138822
View directory record Official record
Conditions
Uncomplicated Urinary Tract Infections, Urinary Tract Infections
Interventions
GSK3882347, Nitrofurantoin, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
15
States / cities
Anniston, Alabama • Lomita, California • Modesto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jun 26, 2026, 2:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Recombinant Vaccine to Prevent ETEC Diarrhea

NCT01382095
View directory record Official record
Conditions
Escherichia Coli Infection
Interventions
Recombinant fimbrial adhesin dscCfaE, Modified E. coli heat labile enterotoxin LTR192G
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 26, 2015 · Synced Jun 26, 2026, 2:33 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Study to Assess the Efficacy of Once-daily IMM-124E (Travelan®) in a Controlled Human Infection Model.

NCT05933525
View directory record Official record
Conditions
Diarrhea, Travelers Diarrhea, Infectious Diarrhea
Interventions
Travelan, Placebo
Biological · Other
Lead sponsor
Immuron Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jun 26, 2026, 2:33 AM EDT
Completed No phase listed Observational

Antibiotic Resistant Community-Acquired E. Coli

NCT00298103
View directory record Official record
Conditions
E Coli Infection
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 16, 2015 · Synced Jun 26, 2026, 2:33 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant

NCT06938867
View directory record Official record
Conditions
E Coli Infections, Allogenic Transplant Patients
Interventions
SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coli, Placebo 10 mL
Biological · Other
Lead sponsor
SNIPR Biome Aps.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
8
States / cities
Duarte, California • San Francisco, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jun 26, 2026, 2:33 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years

NCT04899336
View directory record Official record
Conditions
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Interventions
ExPEC9V, Placebo
Biological · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
60 Years and older
Enrollment
17,935 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
142
States / cities
Guntersville, Alabama • Phoenix, Arizona • Sun City West, Arizona + 100 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 26, 2026, 2:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Experiment of Helicobacter Pylori Transmission

NCT00550368
View directory record Official record
Conditions
Infection, Achlorhydria
Interventions
Biological intervention: Enteropathogenic E. coli
Biological
Lead sponsor
Stanford University
Other
Eligibility
35 Years to 59 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Jun 26, 2026, 2:33 AM EDT
Withdrawn No phase listed Observational

Ampicillin-sulbactam Resistant E.Coli at UPMC

NCT00619580
View directory record Official record
Conditions
Positive E Coli Infections
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 7, 2014 · Synced Jun 26, 2026, 2:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dose Escalating Study of a Prototype CS6 Subunit Vaccine With a Modified Heat-labile Enterotoxin From Enterotoxigenic Escherichia Coli (ETEC)

NCT03404674
View directory record Official record
Conditions
Diarrhea
Interventions
CssBA, dmLT
Biological
Lead sponsor
PATH
Other
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Jun 26, 2026, 2:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects

NCT05277350
View directory record Official record
Conditions
E.Coli Infections, Bloodstream Infection
Interventions
SNIPR001, Placebo
Drug
Lead sponsor
SNIPR Biome Aps.
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Jun 26, 2026, 2:33 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study Confirming A Human Challenge Model and Investigating The Safety Of VLA1701

NCT03576183
View directory record Official record
Conditions
Enterotoxigenic Escherichia Coli Infection, Diarrhea
Interventions
VLA1701, Placebo, Challenge Strain
Biological · Other
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
18 Years to 49 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Jun 26, 2026, 2:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Safety, Reactogenicity and Immunogenicity of Fractional-dose Inactivated Polio Vaccine (fIPV) Given Intradermally With Double Mutant Enterotoxigenic Escherichia Coli Heat Labile Toxin (dmLT) Adjuvant

NCT03922061
View directory record Official record
Conditions
Polio
Interventions
dmLT, fIPV
Biological
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 45 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Jun 26, 2026, 2:33 AM EDT
Completed No phase listed Observational

Epidemiology of Community - Associated Extended-spectrum Beta-lactamases (ESBL) Producing Escherichia Coli

NCT00573235
View directory record Official record
Conditions
Enterobacteriaceae Infections
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Jun 26, 2026, 2:33 AM EDT
Recruiting Not applicable Interventional

Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection

NCT05219110
View directory record Official record
Conditions
Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection, Hemolytic-Uremic Syndrome
Interventions
Infusion of 200% maintenance fluids as balanced crystalloid IV solution, Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution
Other
Lead sponsor
University of Calgary
Other
Eligibility
9 Months to 21 Years
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
22
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jun 26, 2026, 2:33 AM EDT
Recruiting Phase 1 Interventional

Bacteriophage Therapy in Spinal Cord Injury Patients With Bacteriuria

NCT06559618
View directory record Official record
Conditions
Bacteriuria, Spinal Cord Injuries, Asymptomatic Bacteriuria, Escherichia Coli
Interventions
Phage Therapy, Placebo
Drug · Other
Lead sponsor
Barbara Trautner
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
St Louis, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 26, 2026, 2:33 AM EDT
Recruiting Phase 2 Interventional

A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)

NCT05488340
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
LBP-EC01 0.1 x IV dose, LBP-EC01 0.01x IV Dose, LBP-EC01 IV Infusion Dose, Placebo, LBP-EC01, TMP/SMX
Drug
Lead sponsor
Locus Biosciences
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
17
States / cities
Fresno, California • Lancaster, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jun 26, 2026, 2:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Shigella CVD 31000: Study of Responses With Shigella-ETEC Vaccine Strain CVD 1208S-122

NCT04634513
View directory record Official record
Conditions
Shigella Infection, Enterotoxigenic Escherichia Coli Infection
Interventions
strain CVD 1208S-122, Placebo
Biological · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 49 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Jun 26, 2026, 2:33 AM EDT
Completed No phase listed Observational

Multi-Drug Resistant Organism (MDRO): Study of Highly Resistant Escherichia Coli

NCT04574596
View directory record Official record
Conditions
E Coli Infection
Interventions
no Intervention
Other
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
300 participants
Timeline
2020 – 2021
U.S. locations
13
States / cities
Torrance, California • Aurora, Colorado • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Jun 26, 2026, 2:33 AM EDT
Completed No phase listed Observational

Community - Associated Extended-spectrum Beta-lactamases (ESBL)

NCT00363220
View directory record Official record
Conditions
Infection, E Coli Infections, Klebsiella Infections, Proteus Infections
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 16, 2015 · Synced Jun 26, 2026, 2:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Trial of a Falciparum Malaria Protein (FMP012), E. Coli-expressed PfCelTOS, in Healthy Malaria-Naive Adults

NCT01540474
View directory record Official record
Conditions
Malaria
Interventions
Group 1: 10 ug FMP012 with 2 ug GLA-SE, Group 2: 10 ug FMP012 with 5 ug GLA-SE, 50 ug FMP012 with 5 ug GLA-SE or 2 ug GLA-SE, Controlled group-Challenged Only: no vaccination
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Jun 26, 2026, 2:33 AM EDT
Terminated Phase 3 Interventional

Phase III Randomized Study of SYNSORB Pk in Children With E. Coli-Associated Hemolytic Uremic Syndrome

NCT00004465
View directory record Official record
Conditions
Hemolytic Uremic Syndrome
Interventions
SYNSORB Pk, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Months to 18 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
26
States / cities
Denver, Colorado • Wilmington, Delaware • Atlanta, Georgia + 23 more
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Jun 26, 2026, 2:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

ACE527 Safety and Immunogenicity Study

NCT00901654
View directory record Official record
Conditions
Enterotoxigenic E. Coli (ETEC) Infection
Interventions
ACE527 vaccine, Placebo vaccine
Biological
Lead sponsor
TD Vaccines A/S
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 28, 2010 · Synced Jun 26, 2026, 2:33 AM EDT
Completed Phase 1 Interventional Results available

Bacterial Interference for Prevention of Catheter-Associated UTI: Geriatric Pilot Study

NCT00554996
View directory record Official record
Conditions
Urinary Tract Infection
Interventions
E. coli 83972 coated urinary catheter
Device
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Jun 26, 2026, 2:33 AM EDT